All Title Author
Keywords Abstract

PLOS ONE  2012 

HLA Associations in Classical Hodgkin Lymphoma: EBV Status Matters

DOI: 10.1371/journal.pone.0039986

Full-Text   Cite this paper   Add to My Lib

Abstract:

The pathogenesis of classical Hodgkin lymphoma (cHL) involves environmental and genetic factors. To explore the role of the human leukocyte antigen (HLA) genes, we performed a case-control genotyping study in 338 Dutch cHL patients using a PCR-based sequence-specific oligonucleotide probe (SSOP) hybridization approach. The allele frequencies were compared to HLA typings of more than 6,000 controls. The age of the cHL patients varied between 13 and 81 years with a median of 35 years. Nodular sclerosis subtype was the most common subtype (87%) and EBV was detected in 25% of the cHL patients. HLA-B5 was significantly increased and HLA-DR7 significantly decreased in the total cHL patient population as compared to controls. Two class II associations were observed to be specific for the EBV? cHL population with an increase of HLA-DR2 and HLA-DR5. Allele frequencies of HLA-A1, HLA-B37 and HLA-DR10 were significantly increased in the EBV+ cHL population; these alleles are in strong linkage disequilibrium and form a common haplotype in Caucasians. The allele frequency of HLA-A2 was significantly decreased in the EBV+ cHL population. Analysis of haplotypes with a frequency of >1% revealed a significant increase of HLA-A2-B7-DR2 in EBV? cHL as compared to controls. SSOP association analysis revealed significant differences between EBV+ and EBV? cHL patients for 19 probes that discriminate between HLA-A*01 and HLA-A*02. In conclusion, the HLA-A1 and HLA-A2 antigens and not specific single nucleotide variants shared by multiple alleles are responsible for the association with EBV+ cHL. Furthermore several new protective and predisposing HLA class I and II associations for the EBV+, the EBV? and the entire cHL population were identified.

References

[1]  Landgren O, Caporaso NE (2009) New aspects in descriptive, etiologic, and molecular epidemiology of Hodgkin's lymphoma. Hematol Oncol Clin North Am 21: 825–840.
[2]  Kuppers R (2009) The biology of Hodgkin's lymphoma. Nat Rev Cancer 9: 15–27.
[3]  Sonmez M, Erkut N, Ucar F, Buruk K, Cobanoglu U, et al. (2010) Familial Hodgkin's lymphoma from the perspective of HLA. Intern Med 49: 607–610.
[4]  Cartwright RA, Watkins G (2004) Epidemiology of Hodgkin's disease: a review. Hematol Oncol 22: 11–26.
[5]  Diepstra A, Niens M, Vellenga E, van Imhoff GW, Nolte IM, et al. (2005) Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma. Lancet 365: 2216–2224.
[6]  Diepstra A, Niens M, Te Meerman GJ, Poppema S, van den Berg A (2005) Genetic susceptibility to Hodgkin's lymphoma associated with the human leukocyte antigen region. Eur J Haematol. pp. 34–41.
[7]  Harty LC, Lin AY, Goldstein AM, Jaffe ES, Carrington M, et al. (2002) HLA-DR, HLA-DQ, and TAP genes in familial Hodgkin disease. Blood 99(2): 690–693.
[8]  Depil S, Morales O, Auriault C (2004) Hodgkin's disease and Epstein-Barr virus. Ann Biol Clin (Paris) 62: 639–648.
[9]  Lee SP, Tierney RJ, Thomas WA, Brooks JM, Rickinson AB (1997) Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. J Immunol 158: 3325–3334.
[10]  Voo KS, Fu T, Wang HY, Tellam J, Heslop HE, et al. (2004) Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes. J Exp Med 199: 459–470.
[11]  Kruger S, Schroers R, Rooney CM, Gahn B, Chen SY (2003) Identification of a naturally processed HLA-DR-restricted T-helper epitope in Epstein-Barr virus nuclear antigen type 1. J Immunother 26: 212–221.
[12]  Marshall WH, Barnard JM, Buehler SK, Crumley J, Larsen B (1997) HLA in familial Hodgkin's disease. Results and a new hypothesis. Int J Cancer 19: 450–455.
[13]  Hansen JA, Young CW, Whitsett C, Case DC Jr, Jersild C, et al. (1977) HLA and MLC typing in patients with Hodgkin's disease. Prog Clin Biol Res 16: 217–227.
[14]  Hafez MM, el-Wehedy GF, el-Kholy NM, el-Shawaf IM, Mahmoud ME, et al. (1985) The value of HLA phenotypes in the prognosis of Hodgkin's lymphoma. Int J Cancer 36: 19–22.
[15]  Niens M, van den Berg A, Diepstra A, Nolte IM, van der Steege G, et al. (2006) The human leukocyte antigen class I region is associated with EBV-positive Hodgkin's lymphoma: HLA-A and HLA complex group 9 are putative candidate genes. Cancer Epidemiol Biomarkers Prev 15: 2280–2284.
[16]  Niens M, Jarrett RF, Hepkema B, Nolte IM, Diepstra A, et al. (2007) HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma. Blood 110: 3310–3315.
[17]  Hjalgrim H, Rostgaard K, Johnson PC, Lake A, Shield L, et al. (2010) HLA-A alleles and infectious mononucleosis suggest a critical role for cytotoxic T-cell response in EBV-related Hodgkin lymphoma. Proc Natl Acad Sci U S A 107: 6400–6405.
[18]  Enciso-Mora V, Broderick P, Ma Y, Jarrett RF, Hjalgrim H, et al. (2010) A genome-wide association study of Hodgkin Lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21, and 10p14 (GATA3). Nature Genetics 42(12): 1126–1130.
[19]  Urayama KY, Jarrett RF, Hjalgrim H, Diepstra A, Kamatani Y, et al. (2012) Genome-wide association study of classical Hodgkin lymphoma and Epstein-Barr virus status-defined subgroups. J Natl Cancer Inst 104(3): 240–253.
[20]  Helmberg W, Lanzer G, Zahn R, Weinmayr B, Wagner T, et al. (1998) Virtual DNA analysis – a new tool for combination and standardised evaluation of SSO, SSP and sequencing-based typing results. Tissue Antigens 51: 587–592.
[21]  Bjorkman PJ, Parham P (1990) Structure, function, and diversity of class I major histocompatibility complex molecules. Annu Rev Biochem 59: 253–288.
[22]  Cano P, Klitz W, Mack SJ, Maiers M, Marsh SG, et al. (2007) Common and well-documented HLA alleles: report of the Ad-Hoc committee of the american society for histocompatiblity and immunogenetics. Hum.Immunol 68: 392–417.
[23]  Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559–575.
[24]  Stephens M, Scheet P (2005) Accounting for decay of linkage disequilibrium in haplotype inference and missing data imputation. Am J Hum Genet 76: 449–462.
[25]  Stephens M, Smith NJ, Donnelly P (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68: 978–989.
[26]  Schipper RF, Schreuder GMT, D'Amoro J, Oudshoorn (1996) HLA gene and haplotype frequencies in Dutch blood donors. Tissue Antigens 48: 562–574.
[27]  Ghodke Y, Joshi K, Chopra A, Patwardhan B (2005) HLA and disease. Eur J Epidemiol 20: 475–488.
[28]  Huang X, Hepkema B, Nolte I, Kushekhar K, Jongsma T, et al. (2012) HLA-A*02:07 is a protective allele for EBV negative and a susceptibility allele for EBV positive classical Hodgkin lymphoma in China. PLoS One 7(2): e31865.
[29]  Marescotti D, Destro F, Baldisserotto A, Marastoni M, Coppotelli G, et al. (2010) Characterization of an human leucocyte antigen A2-restricted Epstein-Barr virus nuclear antigen-1-derived cytotoxic T-lymphocyte epitope. Immunology 129(3): 386–395.
[30]  Bell MJ, Abbott RJ, Croft NP, Hislop AD, Burrows SR (2009) An HLA-A2-restricted T-cell epitope mapped to the BNLF2a immune evasion protein of Epstein-Barr virus that inhibits TAP. J Virol 83(6): 2783–2788.
[31]  Rickinson AB, Moss DJ (1997) Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 15: 405–431.
[32]  Hildesheim A, Apple RJ, Chen CJ, Wang SS, Cheng YJ, et al. (2002) Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst 94: 1780–1789.
[33]  Burt RD, Vaughan TL, McKnight B, Davis S, Beckmann AM, et al. (1996) Associations between human leukocyte antigen type and nasopharyngeal carcinoma in Caucasians in the United States. Cancer Epidemiol Biomarkers Prev 5: 879–887.
[34]  Murray RJ, Wang D, Young LS, Wang F, Rowe M, et al. (1988) Epstein-Barr virus-specific cytotoxic T-cell recognition of transfectants expressing the virus-coded latent membrane protein LMP. J Virol 62: 3747–3755.
[35]  Hors J, Dausset J (1983) HLA and susceptibility to Hodgkin's disease. Immunol Rev 70: 167–92.
[36]  Robertson SJ, Lowman JT, Grufferman S, Kostyu D, van der Horst CM, et al. (1987) Familial Hodgkin's disease. A clinical and laboratory investigation. Cancer 59: 1314–1319.

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

微信:OALib Journal